New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer

Rheumatol Int. 2008 Sep;28(11):1127-35. doi: 10.1007/s00296-008-0589-5. Epub 2008 May 7.

Abstract

It is considered that the mechanism in intractable cutaneous ulcer is deeply associated with prolongation at the inflammatory phase. Having evaluated the effects of Lipo-prostaglandin E1 (Lipo-PGE1) with indicators such as the reduction ratio of the ulcer area and the values of the inflammatory markers after dividing them into two groups of collagen diseases and non-collagen diseases and giving them Lipo-PGE1, we managed to obtain the result that Lipo-PGE1 administration could influence various inflammatory markers such as C-reactive protein (CRP), IL-6, and VEGF in addition to reduction of the ulcer region. It also suggested that Lipo-PGE1 has the effect of maintaining an appropriate balance of induction of inflammation and angiogenesis. Additionally, it revealed that Lipo-PGE1 controls the production of cytokines, which are associated with the growth of collagen diseases. From these results, it can be expected that Lipo-PGE1 will act favorably on intractable collagen diseases.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alprostadil / therapeutic use*
  • Anti-Inflammatory Agents / therapeutic use*
  • C-Reactive Protein / analysis
  • Cohort Studies
  • Collagen Diseases / complications*
  • Female
  • Humans
  • Intercellular Adhesion Molecule-1 / blood
  • Interleukin-6 / blood
  • Male
  • Middle Aged
  • Rheumatic Diseases / complications*
  • Skin Ulcer / complications*
  • Skin Ulcer / drug therapy*
  • Skin Ulcer / immunology
  • Vascular Endothelial Growth Factor A / blood

Substances

  • Anti-Inflammatory Agents
  • IL6 protein, human
  • Interleukin-6
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Intercellular Adhesion Molecule-1
  • C-Reactive Protein
  • Alprostadil